Rasbach Kyle 4
4 · Lexeo Therapeutics, Inc. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Rasbach Kyle
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-17+245,250→ 245,250 totalExercise: $5.07Exp: 2035-01-16→ Common Stock (245,250 underlying) - Award
Common Stock
2025-01-17+40,875→ 40,875 total
Footnotes (3)
- [F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]The reported securities are RSUs.
- [F3]25% of the shares underlying the option vest and become exercisable on December 18, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.